Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C R. Divgi

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1991
A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclideD A Scheinberg, D Lovett, C R Divgi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1993
Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemiasM A Schwartz, D R Lovett, A Redner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1994
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblastsS Welt, C R Divgi, A M Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphomaM S Czuczman, D J Straus, C R Divgi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancerS Welt, C R Divgi, N Kemeny, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1996
Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancerS Welt, A M Scott, C R Divgi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 1993
Lesion-by-lesion comparison of computerized tomography and indium-111-labeled monoclonal antibody C110 radioimmunoscintigraphy in colorectal carcinoma: a multicenter trialC R Divgi, K McDermott, T W Griffin, et al.
Blood|April 1, 1994
A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicityP C Caron, J G Jurcic, A M Scott, et al.
British Journal of Clinical Pharmacology|March 22, 2001
Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patientsP Tanswell, P Garin-Chesa, W J Rettig, et al.
Cancer|December 24, 1997
Single chain antigen binding protein (sFv CC49): first human studies in colorectal carcinoma metastatic to liverS M Larson, A M El-Shirbiny, C R Divgi, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1991
A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclideD A Scheinberg, D Lovett, C R Divgi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1993
Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemiasM A Schwartz, D R Lovett, A Redner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1994
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblastsS Welt, C R Divgi, A M Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphomaM S Czuczman, D J Straus, C R Divgi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancerS Welt, C R Divgi, N Kemeny, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1996
Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancerS Welt, A M Scott, C R Divgi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 1993
Lesion-by-lesion comparison of computerized tomography and indium-111-labeled monoclonal antibody C110 radioimmunoscintigraphy in colorectal carcinoma: a multicenter trialC R Divgi, K McDermott, T W Griffin, et al.
Blood|April 1, 1994
A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicityP C Caron, J G Jurcic, A M Scott, et al.
British Journal of Clinical Pharmacology|March 22, 2001
Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patientsP Tanswell, P Garin-Chesa, W J Rettig, et al.
Cancer|December 24, 1997
Single chain antigen binding protein (sFv CC49): first human studies in colorectal carcinoma metastatic to liverS M Larson, A M El-Shirbiny, C R Divgi, et al.
Pageof 5